Véronique Minard-Colin

Véronique Minard-Colin is Professor of Pediatrics in the Children and Adolescent Oncology Department at Gustave Roussy, Villejuif, France, a large cancer center with 11,000 new patients annually, including 400 children and adolescents. She completed her medical studies with a PhD thesis in immunology and a fellowship in the Thomas F. Tedder Lab (Duke University, Durham, NC, USA). 

For the last 10 years, Prof. Minard-Colin has dedicated her research, clinical, and training activities to non-Hodgkin lymphoma, softtissue sarcoma, and Immunotherapy for children and adolescents with cancer. Together with Florent Ginhoux, PhD, she coordinates the Pediatric Immunology Program in Gustave Roussy, which aims to better understand, through innovative approaches, the mechanisms of cancers immune evasion in children to develop effective  mmunotherapies. 

Prof. Minard-Colin is the international co-coordinator of the Inter-BNHL ritux 2010 trial testing rituximab in children/adolescent with high-risk mature B NHL recently published in the NEJM, and the Nivo ALCL trial with nivolumab in  elapsed/refractory ALK+ anaplastic large cell lymphoma. She is also the chair of the steering committee of the first international Phase 2 Novartis-sponsored trial with CD19 CAR T cells in relapsed/refractory mature B NHL and the French coordinator of the International FaR-RMS trial in rhabdomyosarcoma.

Prof. Minard-Colin was elected in 2019 vice-president of the French Society of Childhood Cancers (SFCE) and she is a member of several European Boards including the European childhood non-Hodgkinien lymphoma (EICNHL) and of the European Pediatric Sarcoma

Soft Tissues Study Group (EpSSG). She joined the scientific advisory committee of the International Society of Paediatric Oncology (SIOP) in 2018 and since 2020, she is a member of the educational council of SIOP Europe. Prof. Minard-Colin is author and coauthor of ~150 publications referenced in PubMed.